Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1053423.RAkLstNUL2SQSFNtQTsLcuwiBEcnhmO1DH61X2agTEnDk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1053423.RAkLstNUL2SQSFNtQTsLcuwiBEcnhmO1DH61X2agTEnDk130_assertion type Assertion NP1053423.RAkLstNUL2SQSFNtQTsLcuwiBEcnhmO1DH61X2agTEnDk130_head.
- NP1053423.RAkLstNUL2SQSFNtQTsLcuwiBEcnhmO1DH61X2agTEnDk130_assertion description "[The most frequent adverse events were acneiform dermatitis (18 [60%] patients with NRAS -mutated melanoma and 15 [37%] patients with the BRAF-mutated melanoma), rash (six [20%] and 16 [39%]), peripheral oedema (ten [33%] and 14 [34%]), facial oedema (nine [30%] and seven [17%]), diarrhoea (eight [27%] and 15 [37%]), and creatine phosphokinase increases (11 [37%] and nine [22%]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1053423.RAkLstNUL2SQSFNtQTsLcuwiBEcnhmO1DH61X2agTEnDk130_provenance.
- NP1053423.RAkLstNUL2SQSFNtQTsLcuwiBEcnhmO1DH61X2agTEnDk130_assertion evidence source_evidence_literature NP1053423.RAkLstNUL2SQSFNtQTsLcuwiBEcnhmO1DH61X2agTEnDk130_provenance.
- NP1053423.RAkLstNUL2SQSFNtQTsLcuwiBEcnhmO1DH61X2agTEnDk130_assertion SIO_000772 23414587 NP1053423.RAkLstNUL2SQSFNtQTsLcuwiBEcnhmO1DH61X2agTEnDk130_provenance.
- NP1053423.RAkLstNUL2SQSFNtQTsLcuwiBEcnhmO1DH61X2agTEnDk130_assertion wasDerivedFrom befree-2016 NP1053423.RAkLstNUL2SQSFNtQTsLcuwiBEcnhmO1DH61X2agTEnDk130_provenance.
- NP1053423.RAkLstNUL2SQSFNtQTsLcuwiBEcnhmO1DH61X2agTEnDk130_assertion wasGeneratedBy ECO_0000203 NP1053423.RAkLstNUL2SQSFNtQTsLcuwiBEcnhmO1DH61X2agTEnDk130_provenance.